Janssen gets expanded authorization for Genmab's Darzalex in EU
![Photo: Tuala Hjarnø / Genmab / PR](https://photos.watchmedier.dk/watchmedier/resize:fill:3840:0:0/plain/https://photos.watchmedier.dk/Images/article13078659.ece/ALTERNATES/schema-16_9/doc7gc6rpfbjkg589csdu0.jpg)
Genmab's collaborative partner Janssen has received a European marketing Authorization for Darzalex for treating the rare disease Light-chain (AL) amyloidosis.
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
Get full access for you and your coworkers
Start a free company trial todayRelated articles
Bavarian Nordic: Vaccine production almost came to Denmark
For subscribers